Ventilator-Associated Pneumonia Market Research Report - Forecast till 2027

Ventilator-Associated Pneumonia Market Research Report: Information by Diagnosis (Clinical, Radiological, Microbiological), End User (Hospitals & Clinics, Research & Academic Institutes, Ambulatory Care Centers), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0868-HCR | February 2021 | Region: Global | 110 pages

Impact of Covid-19 Outbreak on Global Ventilator-Associated Pneumonia (VAP) Market


The COVID-19 epidemic has been straining healthcare workflow across the globe. The outbreak has forced various industries to shut its doors, including many healthcare subdomains temporarily. Parallel to this, it has also had a positive impact and increasing demand for various medical market segments, including intensive care unit devices (beds, ventilators, etc.) and personal healthcare protection equipment, among others. A medical ventilator is one of the major devices that is used for the treatment of COVID-19. There has been a tremendous increasing demand for medical ventilators, forcing various manufacturers to boost their production by 30% to 50%. Various major players are pushing themselves for manufacturing and delivering as many possible ventilators across the world. The increasing usage of ventilators in healthcare facilities is increasing the chances of patients infected with ventilator-associated pneumonia.


Regional impact of COVID-19 pneumonia


China


In China, many hospitals have estimated that the incidences of pneumonia increase the death rate in COVID-19 patients. In February 2020, a research study conducted in Wuhan Pulmonary Hospital estimated about 76% were diagnosed with COVID-19 pneumonia. COVID-19-induced pneumonia requires medicines that cure pneumonia symptoms.


US


The US is one of the major countries that has been impacted by COVID-19. There is a huge need for medical ventilators across the country. According to Wall Streets, it is expected that the US is purchasing more than USD 2.5 billion in ventilators for COVID-19 patients. This increasing use of ventilators may lead to chances of ventilator-associated pneumonia in this region.


India


The number of infected in India is growing. According to a research study published by the Indian Council of Medical Research (ICMR), estimated that about 40% of total COVID-19 patients suffer from symptoms similar to pneumonia. This large number of COVID-19 cases is expected to boost the growth of the pneumonia market in India.


Companies taking opportunity over the covid-19 situation




  • Hoffmann-La Roche AG



  • Hoffmann-La Roche AG is a leading manufacturer of pharmaceutical drugs. On 19 March 2020, the company initiated its phase 3 clinical trials for Actemra/RoActemra in hospitalized patients with severe COVID-19 pneumonia. This helped the company launch innovative drugs in the category of pneumonia. With this announcement of new clinical trials, the company is accelerated manufacturing capacity to maximize the production of Actemra and ensure that it will be available drugs across the globe.


Novartis


On 28 April 2020, the company announced plans to initiate a phase III clinical trial of canakinumab for patients suffering from COVID-19 pneumonia. This initiative is likely to help the company gain the maximum share in the market.


Merck & Co., Inc.


In June 2019, Merck & Co., Inc. received the US Food and Drug Administration (FDA) approvals for Zerbaxa for treating hospital-acquired and ventilator-associated bacterial pneumonia. As many COVID-19 patients suffer from pneumonia, this drug could help patients to relieve their symptoms of pneumonia.

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis


6. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS

6.1. Overview

6.2. Clinical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Radiological

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Microbiological

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.1. Blood and pleural fluid cultures

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.2. Nonquantitative or semi quantitative airway sampling

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.3. Quantitative cultures of airway specimens

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Ambulatory Care Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Ventilator-Associated Pneumonia Market

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Ventilator-Associated Pneumonia Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2020

9.8.2. Major Players R&D Expenditure 2020

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Adenium Biotech ApS

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Merck & Co., Inc.

10.2.1. Company Overview

10.2.2. Product Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. AstraZeneca

10.3.1. Company Overview

10.3.2. Product Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. MedImmune

10.4.1. Company Overview

10.4.2. Product Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Nabriva Therapeutics AG

10.5.1. Company Overview

10.5.2. Product Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Thermo Fisher Scientific

10.6.1. Company Overview

10.6.2. Product Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Bayer AG

10.7.1. Company Overview

10.7.2. Product Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Wockhardt

10.8.1. Company Overview

10.8.2. Product Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Shionogi Inc.

10.9.1. Company Overview

10.9.2. Product Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Cardeas Pharma

10.10.1. Company Overview

10.10.2. Product Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Others

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 NORTH AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 US: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 9 US: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 CANADA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 11 CANADA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 LATIN AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 13 LATIN AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 15 EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 WESTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 17 WESTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 18 EASTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 19 EASTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET

FIGURE 4 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY DIAGNOSIS, 2020 (%)

FIGURE 5 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 8 EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 WESTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 ASIA-PACIFIC: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 MIDDLE EAST & AFRICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 ADENIUM BIOTECH APS.: KEY FINANCIALS

FIGURE 14 ADENIUM BIOTECH APS: SEGMENTAL REVENUE

FIGURE 15 ADENIUM BIOTECH APS: REGIONAL REVENUE

FIGURE 16 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 17 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 18 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 19 ASTRAZENECA: KEY FINANCIALS

FIGURE 20 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 21 ASTRAZENECA: REGIONAL REVENUE

FIGURE 22 MEDIMMUNE: KEY FINANCIALS

FIGURE 23 MEDIMMUNE: SEGMENTAL REVENUE

FIGURE 24 MEDIMMUNE: REGIONAL REVENUE

FIGURE 25 NABRIVA THERAPEUTICS AG: KEY FINANCIALS

FIGURE 26 NABRIVA THERAPEUTICS AG: SEGMENTAL REVENUE

FIGURE 27 NABRIVA THERAPEUTICS AG: REGIONAL REVENUE

FIGURE 28 THERMO FISHER SCIENTIFIC: KEY FINANCIALS

FIGURE 29 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE

FIGURE 30 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE

FIGURE 31 BAYER AG: KEY FINANCIALS

FIGURE 32 BAYER AG: SEGMENTAL REVENUE

FIGURE 33 BAYER AG: REGIONAL REVENUE

FIGURE 34 WOCKHARDT: KEY FINANCIALS

FIGURE 35 WOCKHARDT: SEGMENTAL REVENUE

FIGURE 36 WOCKHARDT: REGIONAL REVENUE

FIGURE 37 SHIONOGI INC.: KEY FINANCIALS

FIGURE 38 SHIONOGI INC.: SEGMENTAL REVENUE

FIGURE 39 SHIONOGI INC.: REGIONAL REVENUE

FIGURE 40 CARDEAS PHARMA: KEY FINANCIALS

FIGURE 41 CARDEAS PHARMA: SEGMENTAL REVENUE

FIGURE 42 CARDEAS PHARMA: REGIONAL REVENUE